The approach to the treatment of metastatic hormone-sensitive prostate cancer (mHSPC) has undergone a dramatic transformation over the last few years.  This is probably most surprising because of the lack of therapeutic developments for those patients for several decades prior. 

E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe